Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.
Epistemonikos ID: d6e52642f4c90f98a3c948c7c6fd3cef144e1186
First added on: Feb 19, 2024